{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:10:57Z","timestamp":1792750257929,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score\u2009+\u2009neutrophil-to-lymphocyte ratio\u2009+\u2009bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>CESC IOV 2023-78.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12319-1","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:02:05Z","timestamp":1719208925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma \u2013 Meet-URO 33 study (REGAL study)"],"prefix":"10.1186","volume":"24","author":[{"given":"Sara Elena","family":"Rebuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvise","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"12319_CR1","doi-asserted-by":"publisher","first-page":"175883592090750","DOI":"10.1177\/1758835920907504","volume":"12","author":"E Rassy","year":"2020","unstructured":"Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504.","journal-title":"Ther Adv Med Oncol"},{"key":"12319_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11523-019-00653-5","volume":"14","author":"M Moran","year":"2019","unstructured":"Moran M, Nickens D, Adcock K, et al. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data. Target Oncol. 2019;14:405\u201316.","journal-title":"Target Oncol"},{"issue":"5","key":"12319_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2019.06.022","volume":"2","author":"G de Velasco","year":"2019","unstructured":"de Velasco G, Bex A, Albiges L, et al. Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur Urol Oncol. 2019;2(5):505\u201314. https:\/\/doi.org\/10.1016\/j.euo.2019.06.022.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"12319_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cancers12010143","volume":"12","author":"R Garje","year":"2020","unstructured":"Garje R, An J, Greco A, Vaddepally RK, Zakharia Y. The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma. Cancers (Basel). 2020;12(1):143. https:\/\/doi.org\/10.3390\/cancers12010143.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"12319_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"key":"12319_CR6","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156\u201367.","journal-title":"Cancer"},{"issue":"5","key":"12319_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network Meta-analysis. Eur Urol Oncol. 2021;4(5):755\u201365.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"12319_CR8","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus Ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. https:\/\/doi.org\/10.1136\/esmoopen-2020-001079.","journal-title":"ESMO Open"},{"issue":"12","key":"12319_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, et al. Pembrolizumab plus Axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(20)30436-8.","journal-title":"Lancet Oncol"},{"issue":"12","key":"12319_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al. KEYNOTE-426 investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"7","key":"12319_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X.","journal-title":"Lancet Oncol"},{"issue":"3","key":"12319_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus Pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(23)00049-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"12319_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/OP.21.00419","volume":"18","author":"J Tran","year":"2022","unstructured":"Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18(3):187\u201396.","journal-title":"JCO Oncol Pract"},{"key":"12319_CR14","doi-asserted-by":"publisher","first-page":"102377","DOI":"10.1016\/j.ctrv.2022.102377","volume":"106","author":"P Lombardi","year":"2022","unstructured":"Lombardi P, Filetti M, Falcone R, et al. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancer Treat Rev. 2022;106:102377.","journal-title":"Cancer Treat Rev"},{"key":"12319_CR15","doi-asserted-by":"crossref","unstructured":"Ciccarese C, Iacovelli R, Porta C et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. 2021;100:102295.","DOI":"10.1016\/j.ctrv.2021.102295"},{"key":"12319_CR16","doi-asserted-by":"crossref","unstructured":"Pan E, Urman D, Malvar C, McKay RR. Managing First-Line metastatic renal cell carcinoma: favorable-risk disease. Hematol Oncol Clin North Am 2023;S0889-8588(23)00051\u2009\u2013\u20095.","DOI":"10.1016\/j.hoc.2023.04.017"},{"key":"12319_CR17","doi-asserted-by":"publisher","first-page":"103881","DOI":"10.1016\/j.critrevonc.2022.103881","volume":"181","author":"MD Delcuratolo","year":"2023","unstructured":"Delcuratolo MD, Tucci M, Turco F, et al. Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors. Crit Rev Oncol Hematol. 2023;181:103881.","journal-title":"Crit Rev Oncol Hematol"},{"key":"12319_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","volume":"135","author":"BA McGregor","year":"2020","unstructured":"McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020;135:203\u201310.","journal-title":"Eur J Cancer"},{"key":"12319_CR19","doi-asserted-by":"publisher","first-page":"175883592110196","DOI":"10.1177\/17588359211019642","volume":"13","author":"SE Rebuzzi","year":"2021","unstructured":"Rebuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642.","journal-title":"Ther Adv Med Oncol"},{"key":"12319_CR20","doi-asserted-by":"publisher","first-page":"e071108","DOI":"10.1136\/bmj-2022-071108","volume":"378","author":"AA Matthews","year":"2022","unstructured":"Matthews AA, Danaei G, Islam N, Kurth T. Target trial emulation: applying principles of randomised trials to observational studies. BMJ. 2022;378:e071108.","journal-title":"BMJ"},{"key":"12319_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T. clinicalguidelines@esmo.org EGCommitteeE address: recent eUpdate to the ESMO Clinical Practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:422\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.016.","journal-title":"Ann Oncol"},{"issue":"2","key":"12319_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","volume":"70","author":"K Mori","year":"2021","unstructured":"Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, et al. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2021;70(2):265\u201373. https:\/\/doi.org\/10.1007\/s00262-020-02684-8.","journal-title":"Cancer Immunol Immunother"},{"key":"12319_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2021.06.015","volume":"154","author":"F Massari","year":"2021","unstructured":"Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021;154:120\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.015.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12319-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:03:14Z","timestamp":1719208994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12319"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12319-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Istituto Oncologico Veneto IOV IRCCS of Padua on the 1st of June 2023 (Registrational number: CESC IOV 2023-78).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SER received honoraria as speaker at scientific events and travel accommodation from BMS, Amgen, GSK, Ipsen, Astellas, Janssen and MSD. GF services advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD, Merck and received travel accommodation from Astellas, Janssen, Bayer. DB received honoraria as advisory role by Ipsen, Astellas, Janssen, Novartis, BMS, MSD, Pfizer, Merck and travel accommodation from Ipsen, Janssen, MSD, Merck. UB received honoraria as advisory role by BMS, Novartis, research funding from Ipsen and travel accommodation from BMS, Janssen, Astellas, Ipsen, MSD, Merck, Pfizer, Bayer. SB received honoraria as speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, Roche, Eli Lilly, AstraZeneca, Pierre-Fabre, Novartis, Merck, Gentili, Astellas. GP services advisory boards\/consulting for Astellas, AstraZeneca, BMS, Janssen, IPSEN, Merk, MSD, Novartis, Pfizer. UDG services as advisory\/board member of Astellas, Bayer, BMS, IPSEN, Janssen, Merck, Pfizer, Sanofi, received research grant\/funding to the institution from AstraZeneca, Roche, Sanofi and travel\/accommodations\/expenses from BMS, IPSEN, Janssen, Pfizer. GLB reports personal fees from AstraZeneca and Astellas for speaker bureau. PR services advisory boards for MSD, AstraZeneca and Janssen. The other authors have no conflicts of interest to disclose. The study is conducted in accordance with the Good Clinical Practice (GCP) guidelines, the Helsinki Declaration and the local regulatory requirements for medical research involving human subjects. The documented approval by the local Ethics Committee will be required for each center as a condition for center recruitment. Investigators must inform the patients about the nature, objectives and aims of the study. All patients alive provide written informed consent before the inclusion into the study. The other authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"757"}}